Cost-effectiveness of using continuous positive airway pressure in the treatment of severe obstructive sleep apnoea/hypopnoea syndrome in the UK

J F Guest,1,2 M T Helter,1 A Morga,1 J R Stradling3

ABSTRACT

Objective: A study was undertaken to estimate the cost-effectiveness of using continuous positive airway pressure (CPAP) in the management of patients with severe obstructive sleep apnoea/hypopnoea syndrome (OSAHS) compared with no treatment from the perspective of the UK’s National Health Service (NHS).

Methods: A Markov model was constructed to assess the cost-effectiveness of CPAP compared with no treatment. The model depicted the management of a 55-year-old patient with severe OSAHS as defined by an apnoea-hypopnoea index (AHI) >30 and daytime sleepiness (Epworth Sleepiness Scale score ≥12). The model spans a period of 14 years.

Results: According to the model, 57% of untreated patients are expected to be alive at the end of 14 years compared with 72% of patients treated with CPAP. Untreated patients are expected to cost the NHS £10 645 (95% CI £7988 to £14 098) per patient over 14 years compared with £9672 (95% CI £8057 to £12 860) per CPAP-treated patient. Treatment with CPAP for a period of 1 year was found not to be a cost-effective option since the cost per quality-adjusted life year (QALY) gained is expected to be >£20 000, but after 2 years of treatment the cost per QALY gained is expected to be £10 000 or less and, after 13 years of treatment, CPAP becomes a dominant treatment (i.e., more effective than no treatment for less cost).

Conclusion: Within the limitations of the model, CPAP was found to be clinically more effective than no treatment and, from the perspective of the UK’s NHS, a cost-effective strategy after a minimum of 2 years of treatment.

The nocturnal severity of obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is often defined by the number of events per hour. This could be either the number of oxygen desaturation events (oxygen desaturation index) or the number of apnoeas and hypopnoeas (apnoea-hypopnoea index (AHI)), with arbitrary thresholds to define mild, moderate and severe disease. The daytime symptom severity of OSAHS is often defined by either subjective sleepiness scales (such as the Epworth Sleepiness Scale (ESS)) or by objective tests of propensity to sleep (such as the maintenance of wakefulness test).

Continuous positive airway pressure (CPAP) therapy is the treatment of choice for patients with moderate to severe OSAHS, established through meta-analyses.1,2 In most cases the alternative for patients who cannot tolerate CPAP is no treatment. Against this background, this study estimated the cost-effectiveness of using CPAP in the management of patients with severe OSAHS compared with no treatment in the UK.

METHODS

Perspective

This analysis estimated the direct healthcare costs and benefits of managing OSAHS over a period of 14 years with and without CPAP from the perspective of the UK’s National Health Service (NHS).

Data sources

A systematic literature search was performed using a search term of “obstructive sleep apnoea” plus one of the following: incidence, prevalence, epidemiology, hypertension, cardiovascular event, myocardial infarction (MI), stroke, cerebrovascular event, depression, diabetes, compliance, road traffic accident (RTA), utilities, quality of life, cost-effectiveness, cost-utility, resource utilisation, economic and cost. The search strategy was not limited by year of publication, but only English language papers were included. A manual literature search was also undertaken, based on citations in the published papers.

Economic model

A Markov model was constructed which depicted the management of a 55-year-old patient with severe OSAHS as defined by an AHI >30 and daytime sleepiness (ESS ≥12) (fig 1). Within the model, the time to the start of treatment with CPAP following the initial outpatient visit or diagnostic sleep study (whichever comes first) is 8.4 months (based on information supplied by the interviewees) and the model spans a period of 14 years.

The model comprises the following health states and death:

- Event-free with uncontrolled OSAHS.
- Event-free with controlled OSAHS.
- Stroke.
- Cardiovascular event.
- RTA.
- Survival following stroke, cardiovascular event or RTA.

Patients can initially move into one of four health states (i.e., event-free, stroke, cardiovascular event or RTA) and patients remain in a state for
proved challenging, although epidemiological studies have consistently found an association between OSAHS and cardiovascular disease in patients with untreated severe OSAHS. In a separate study, Mar et al found that the risk of coronary heart disease and stroke in patients with untreated severe OSAHS was 1.185 and 1.353, respectively. Hence, the ratio of developing coronary heart disease to stroke was 1:1.13. In treated patients the risk was 1:1. These ratios were applied to our estimates of the annual incidence of fatal and non-fatal cardiovascular and cerebrovascular events in patients with severe OSAHS, enabling the annual risk of cardiovascular event, stroke, fatality and non-fatality from a cardiovascular and cerebrovascular event to be estimated. These estimates were incorporated into the Markov model and represent the likely maximum effect.

Road traffic accidents

Only two studies were found in which the relative risk of RTAs in patients with OSAHS compared with control populations was reported. The first was a case-control study which found that the risk of an RTA in untreated patients was three times greater than the risk in control populations, while the risk in patients treated with CPAP was the same as that of control populations. In a second study, the number of RTAs in patients with OSAHS was estimated using a road safety platform. The authors estimated that the risk of an RTA in untreated patients was 2.3 times greater than the risk among control populations, whereas the risk in treated patients was marginally less than that of control populations. By taking the average of the findings of these two studies, the model assumes that the risk of an RTA in untreated patients was 2.6 times greater than the risk in control populations, whereas the risk in treated patients was the same as that of control populations.

According to the Department of Transport, there were 221,751 RTAs in Great Britain in 2002 of which 1.3% resulted in a fatality. The distribution of different severities of RTAs (slight, serious and fatal) in Great Britain in 2002 and corresponding costs have been incorporated into the model. In the same year there were 25.3 million licensed motor vehicles in Great Britain. Hence, by assuming that all patients are drivers and have a licensed motor vehicle, it was estimated that the risk of an RTA in the control population (and thus in treated patients with OSAHS) is 0.009 per annum, and 0.023 per annum in untreated patients with OSAHS.

Compliance

Only four published studies were found which reported the percentage of patients with OSAHS who continued using their fixed pressure CPAP device over various periods: 68% over 60 months, 85% over 84 months, 72% over 24 months and 80% over an unspecified period. The average of these four studies was estimated to be 74%. Mc Ardle et al also reported that the percentage of patients who continued using their CPAP device fell from 84% at the end of the first year to 68% after 4 years, remaining at this level for a further 3 years. This equates to a discontinuation rate of 5% per annum over 4 years. Similarly, Krieger et al reported that the percentage of patients who continued using their CPAP device fell from 90% after 5 years to 85% after 7 years, equivalent to a discontinuation rate of 1% per annum over 4 years. The weighted average of these two discontinuation rates was estimated to be 3.8% per annum.

Since the period of the model is >1 year, it was assumed that 74% of all patients would continue using their device during the first year of treatment. It was also assumed that 3.8% of patients receiving CPAP at the beginning of the second year would discontinue using the device during the year, and this
discontinuation rate would decline exponentially over the remaining period of the model.

**Model inputs: resource use**

No publications were identified that quantified healthcare resource use for the management of OSAHS in the UK. This was therefore estimated using information obtained from interviews with 19 randomly selected clinicians from across the UK who managed large established sleep services and who collectively see >6000 new patients with OSAHS per annum. The use of healthcare resources attributable to managing patients with severe OSAHS that has been modelled is summarised in Table 1. According to these clinicians, the shelf life of a CPAP device within their individual hospitals was 7 years, and this was the time frame adopted by the National Institute for Health and Clinical Excellence (NICE) in their health technology appraisal of CPAP. ²⁷

Unit costs at 2005/6 prices incorporated into the model were obtained from the Departments of Health and Transport. ¹² ¹³

The costs of CPAP, humidifier and mask used in the model are the list prices without the application of any discounts often enjoyed by the NHS (ResMed, Oxfordshire, UK, 2007). The hospital cost of an episode of myocardial infarction ²⁰ have been used as proxies for the cost of managing a cardiovascular event.

**Model inputs: health-related quality of life (HRQoL) and utilities**

A Spanish study obtained utility values for different health states from patients with OSAHS who completed the EQ-5D questionnaire before and after they received CPAP treatment. ⁹ In the absence of any other data, these utilities (0.738 for untreated OSAHS, 0.811 for treated OSAHS, 0.590 for non-fatal stroke in untreated OSAHS patients, 0.649 for non-fatal stroke in treated OSAHS patients, 0.664 for non-fatal cardiovascular event in untreated OSAHS patients, 0.750 for non-fatal cardiovascular event in treated OSAHS patients, 0.701 (estimated) for non-fatal RTA in untreated OSAHS patients and 0.771 (estimated) for non-fatal RTA in treated OSAHS patients) were applied to the health states in our Markov model, enabling the level of health gain in terms of the expected number of quality-adjusted life years (QALYs) over 14 years to be estimated.

**Model outputs**

The measures of clinical effectiveness were defined as:

- The expected percentage of surviving patients at 14 years.
- The expected percentage of event-free surviving patients at 14 years.
- The expected number of QALYs at 14 years.

The model also estimated the cumulative risk of having a stroke, cardiovascular event and RTA over 14 years. By incorporating the unit costs into the different states within the Markov model, the expected direct healthcare costs over 14 years were estimated. Costs and consequences that were incurred by patients in the second and subsequent years of the model were discounted by 3.5% in accordance with current UK guidelines. ²¹

**Cost-effectiveness analyses**

The incremental cost-effectiveness of CPAP relative to no treatment was calculated as the difference between the expected cost of the two strategies over 14 years divided by the expected number of QALYs in each state. ²²

### Table 1

<table>
<thead>
<tr>
<th>Resource</th>
<th>Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability of having an initial outpatient visit before a diagnostic sleep study</td>
<td>0.31 (0.11 to 0.51)</td>
</tr>
<tr>
<td>Probability of one outpatient visit after a diagnostic sleep study</td>
<td>0.69 (0.49 to 0.89)</td>
</tr>
<tr>
<td>Probability of a home sleep study</td>
<td>0.75 (0.59 to 0.90)</td>
</tr>
<tr>
<td>Probability of a home titration study</td>
<td>0.99 (0.97 to 1.00)</td>
</tr>
<tr>
<td>Probability of a hospital visit before starting CPAP</td>
<td>0.04 (0 to 0.05)</td>
</tr>
<tr>
<td>Probability of using CPAP (fixed) for titration</td>
<td>0.19 (0.01 to 0.38)</td>
</tr>
<tr>
<td>Probability of using CPAP (auto) for titration</td>
<td>0.81 (0.64 to 0.99)</td>
</tr>
<tr>
<td>Probability of seeing a consultant during the titration phase</td>
<td>0.40 (0.05 to 0.52)</td>
</tr>
<tr>
<td>Probability of seeing a specialist nurse during the titration phase</td>
<td>1.00 (0.53 to 1.00)</td>
</tr>
<tr>
<td>Probability of seeing a technician during the titration phase</td>
<td>0.48 (0.10 to 0.93)</td>
</tr>
<tr>
<td>Probability of having a humidifier</td>
<td>0.38 (0.22 to 0.50)</td>
</tr>
<tr>
<td>Probability of switching from fixed to auto CPAP in the second year</td>
<td>0.06 (0.04 to 0.07)</td>
</tr>
<tr>
<td>Probability of switching from fixed to auto CPAP in subsequent years</td>
<td>0.01 (0 to 0.02)</td>
</tr>
<tr>
<td>Probability of a non-compliant patient returning their machine</td>
<td>0.75 (0.50 to 1.00)</td>
</tr>
<tr>
<td>Probability of having a follow-up visit within 3 months of starting CPAP</td>
<td>0.75 (0.50 to 1.00)</td>
</tr>
<tr>
<td>Probability of having a follow-up visit within 4–6 months of starting CPAP</td>
<td>0.75 (0.75 to 1.00)</td>
</tr>
<tr>
<td>Probability of annual follow-up visits after starting CPAP with a consultant</td>
<td>0.13 (0 to 0.27)</td>
</tr>
<tr>
<td>Probability of annual follow-up visits after starting CPAP with a specialist nurse</td>
<td>0.61 (0.33 to 0.79)</td>
</tr>
<tr>
<td>Probability of annual follow-up visits after starting CPAP with a technician</td>
<td>0.28 (0.09 to 0.54)</td>
</tr>
<tr>
<td>Probability of a deceased patient’s machine being returned</td>
<td>0.90 (0.75 to 1.00)</td>
</tr>
</tbody>
</table>

CPAP, continuous positive airway pressure.

### Table 2

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Probability after 14 years following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>No treatment</td>
<td>CPAP</td>
</tr>
<tr>
<td>Survival</td>
<td>0.57 (0.49 to 0.65)</td>
</tr>
<tr>
<td>Cardiovascular event</td>
<td>0.35 (0.20 to 0.53)</td>
</tr>
<tr>
<td>Stroke</td>
<td>0.39 (0.23 to 0.60)</td>
</tr>
<tr>
<td>RTA</td>
<td>0.24 (0.21 to 0.28)</td>
</tr>
<tr>
<td>Event-free survival</td>
<td>0.30 (0.13 to 0.46)</td>
</tr>
<tr>
<td>QALYs</td>
<td>7.22 (6.48 to 7.93)</td>
</tr>
</tbody>
</table>

95% confidence intervals are shown in parentheses.

CPAP, continuous positive airway pressure; OSAHS, obstructive sleep apnoea/hypopnoea syndrome; RTA, road traffic accident; QALY, quality-adjusted life year.
Table 3  Expected healthcare costs (at 2005/6 prices) over 14 years following no treatment or CPAP

<table>
<thead>
<tr>
<th>Resource</th>
<th>No treatment (£)</th>
<th>CPAP (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinic visits for OSAHS</td>
<td>0.00 (0)</td>
<td>682.22 (7)</td>
</tr>
<tr>
<td>Devices</td>
<td>0.00 (0)</td>
<td>1794.52 (19)</td>
</tr>
<tr>
<td>Diagnostic sleep studies</td>
<td>0.00 (0)</td>
<td>123.60 (1)</td>
</tr>
<tr>
<td>Resources required to manage cardiovascular events</td>
<td>1044.67 (10)</td>
<td>564.50 (6)</td>
</tr>
<tr>
<td>Resources required to manage strokes</td>
<td>7203.58 (68)</td>
<td>4961.12 (51)</td>
</tr>
<tr>
<td>Total</td>
<td>10645.02 (100)</td>
<td>9672.25 (100)</td>
</tr>
</tbody>
</table>

Percentage of total expected cost is shown in parentheses.

Expected healthcare costs

According to the Markov model, untreated patients are expected to cost the NHS £10 645 (95% confidence interval (CI) £7983 to £14 098) per patient over 14 years compared with £9672 (95% CI £8057 to £12 860) per CPAP-treated patient (table 3). For a cost reduction of £973 (95% CI £1983 to £1508) over 14 years, the use of CPAP over 14 years is therefore expected to:

- increase the probability of survival by 25%;
- decrease the relative risk of having a cardiovascular event by 46%;
- decrease the relative risk of having a stroke by 49%;
- decrease the relative risk of having an RTA by 51%;
- increase the probability of event-free survival by 92%.

The total discounted cost for the device, mask, humidifier and sundries was estimated to be £1795 per patient over 14 years. This cost reflects an expectation that the CPAP device would be returned in 75% and 90% of cases where patients either did not comply or died, respectively.

The cost associated with managing stroke was found to be the primary cost driver in both groups. The secondary cost driver in untreated patients was found to be the cost associated with managing RTAs, whereas in CPAP-treated patients it was the cost of the device itself.

The cumulative NHS costs associated with the management of OSAHS accrue over time. The cost of managing patients with CPAP becomes less than that of patients not receiving CPAP treatment by the 13th year owing to the greater number of cardiovascular events, strokes and RTAs in untreated patients.

Cost-effectiveness analyses

The cost-effectiveness analyses of CPAP relative to no treatment show that CPAP affords the NHS a dominant treatment. However, fig 2 illustrates that treatment of CPAP for a period of 1 year is not a cost-effective option since the cost per QALY gained is £20 000. However, after 2 years of treatment the cost per QALY gained is £10 000 or less and, after 15 years of treatment, CPAP becomes a dominant treatment.

Sensitivity analyses

Probabilistic sensitivity analyses showed that CPAP has a 0.99 probability of being cost-effective for a threshold of £20 000 per QALY.

The model incorporated clinical outcomes pertaining to cardiovascular and cerebrovascular events and RTAs from disparate publications. The base case analyses were repeated by removing these outcomes from the model. Even if all cardiovascular and cerebrovascular events and RTAs were excluded from the model, the cost per QALY gained with CPAP relative to no treatment would be £4992 (95% CI £1236 to £5112). Hence, CPAP still affords the NHS a cost-effective technology.

Deterministic sensitivity analyses revealed that changes in some input values had an effect on the relative cost-effectiveness of CPAP, particularly the proportion of patients who continue using CPAP, the risk of having a cardiovascular/cerebrovascular event, the risk of having an RTA, the utility for treated and untreated OSAHS, the cost of managing a non-fatal RTA and the cost of managing stroke rehabilitation. Nevertheless, CPAP ceases to afford the NHS a dominant treatment only when:

- the proportion of patients who continue using CPAP falls below 60% in the first year of treatment;
the relative risk of having a cardiovascular/cerebrovascular event falls to 60% below the base case value;

- the cardiovascular event:stroke ratio among untreated OSAHS patients rises above 1:0.9.

However, in all instances the cost per QALY gained with CPAP is $\leq 5000. The model was insensitive to changes in other model inputs. In particular, the cost-effectiveness of CPAP only changed marginally when changes were made to (1) the time to the start of treatment and (2) all the utility values except that for untreated OSAHS.

The base-case model assumes that the shelf life of CPAP within the NHS is 7 years. However, changing the shelf life to 5 years has a negligible effect on the cost-effectiveness of CPAP. The expected cost to the NHS would rise by £160 to £9833 (95% CI £6229 to £13 060) per patient over 14 years. Nevertheless, CPAP is still expected to afford the NHS a dominant treatment with a cost per QALY of $-942 (95% CI $-2507 to $-4175).

**DISCUSSION**

The model was constructed using information obtained from disparate publications, including the incidence of cardiovascular and cerebrovascular events reported by Marin et al in their uncontrolled observational study. The rationale for using this particular study was that patients were followed for 12 years, which was the longest study we could find. Such observational studies have inherent weaknesses such as a placebo effect, a Hawthorne effect and regression to the mean. Notwithstanding this, the findings of Marin et al were concordant with those of Peker et al. Published randomised trials have reported the effect of CPAP on blood pressure. Accordingly, we could have used Framingham risk equations to provide a link between blood pressure and the incidence of fatal and non-fatal cardiovascular events in a hypothetical cohort of patients. However, we considered that using clinical outcomes from a cohort of patients with OSAHS based on actual clinical practice would lead to fewer assumptions and a model that was more representative of the “real world”. Additionally, the analysis was unable to consider the impact of other co-morbidities, such as diabetes and depression, due to a lack of published evidence.

Our model is subject to several other limitations. Since the clinical basis of the model was disparate published studies and Government statistics, the model may not reflect clinical outcomes observed in clinical practice among a cohort of patients over a period of successive years.

Moreover, it was not possible to model the management of moderate OSAHS owing to the lack of published clinical data required to inform such modelling. We were unable to find any published studies assessing healthcare resource utilisation associated with managing OSAHS in the UK. Hence, this was obtained from interviews with 19 clinicians from across the UK who collectively see >6000 new patients with OSAHS per annum. Utilities were derived from a Spanish population, and these may not be the same as those of a UK population. This gives rise to uncertainty regarding the applicability of these values to a UK study, although sensitivity analyses showed that changing most of these values had minimal impact on the cost-effectiveness of CPAP.

The model used resource estimates and utility values for the “average patient” and did not take into account such factors as age, sex, suitability of patients for different treatments, other disease-related factors, patients’ preferences and level of clinicians’ skills.

The model only considered direct healthcare costs borne by the NHS and not those borne by other Government departments, such as social services costs for rehabilitating patients with stroke and the wider societal costs of RTAs (eg, a fatal RTA can cost >$1 million22). Moreover, the model excluded some primary care costs such as those associated with managing sleepiness, RTAs and cardiovascular events, and this may have underestimated the health economic benefits of CPAP. Also excluded is the cost of any medication including that of antihypertensive drugs required to manage hypertension arising from OSAHS. The model also excluded costs incurred by patients and indirect costs borne by patients or society including the societal cost of sleepiness. If all these costs were factored in, the health economic benefits of CPAP therapy would inevitably be much greater.

Notwithstanding these limitations, our model indicated that treatment with CPAP for a period of 1 year is not a cost-effective option since the cost per QALY gained is $>20 000. However, NICE considers that a technology that has a cost-effectiveness of $<20 000 per QALY potentially affords an effective use of NHS resources.23 The use of CPAP over 14 years is therefore expected to afford the NHS a cost-effective technology since, after 2 years of treatment with CPAP, the cost per QALY gained is $<10 000 and, after 13 years of treatment, CPAP becomes dominant. These findings are concordant with those from four other studies, all of which found CPAP to be a cost-effective treatment.24–26 Sensitivity analyses showed that the relative cost-effectiveness of CPAP is sensitive to continuation rates. Thus, any intervention that improves long-term take-up rates such as better patient education is worth employing.

In conclusion, within the limitations of our model, CPAP was found to be clinically more effective than no treatment and, from the perspective of the NHS in the UK, a cost-effective strategy after a minimum of 2 years of treatment.

**Acknowledgements:** The authors thank the following clinicians for their contributions: Dr B Banerjee, Birmingham Heartlands, Birmingham; Dr B Cooper, Queen Elizabeth Hospital, Birmingham; Dr A Cummin, Charing Cross Hospital, London; Dr C Davies, Royal Berkshire Hospital, Reading; Dr C Dodds, South Cleveland Hospital, Middlesbrough; Dr M Elliott, St James University Hospital, Leeds; Dr P Fitch, Aberdeen Royal Infirmary, Aberdeen; Dr F Gibbon, Freeman Hospital, Newcastle upon Tyne; Dr C Gelder, Llandough Hospital, Cardiff; Dr M A Greenstone, Castle Hill Hospital, Hull; Dr C Manning, Leicester General Hospital, Leicester; Dr A Kendrick, Bristol General Hospital, Bristol; Dr T MacKay, Royal Infirmary of Edinburgh, Edinburgh; Dr J Peppera, Musgrove Park Hospital, Taunton; Dr M Polkey, Royal Brompton Hospital, London; Dr R Royston, Royal National Throat, Nose and Ear Hospital, London; Dr J White, York District General Hospital, York; Dr A Williams, St Thomas’ Hospital, London.

**Funding:** This study was sponsored financially by ResMed, Oxfordshire, UK, manufacturers of CPAP S8 Escape and APAP S8 AutoSet Sprint.

**Competing interests:** None.

**REFERENCES**

When is it too EARLY to start bosentan in pulmonary arterial hypertension?

Pulmonary arterial hypertension is a debilitating progressive disease which eventually leads to right heart failure and death. Although observational studies indicate that early treatment initiation might be advantageous, previous clinical trials only looked at the use of bosentan (dual endothelin receptor antagonist) in patients with advanced symptomatic states (WHO functional class III and IV).

The EARLY trial enrolled 185 patients aged ≥12 years with mildly symptomatic (WHO functional class II) pulmonary arterial hypertension who were randomised to receive either bosentan at an initial dose of 62.5 mg twice daily, up-titrated to 125 mg twice daily after 4 weeks, or placebo for 6 months. Treatment with other approved agents was prohibited with the exception of sildenafil. The primary end point was improvement in exercise capacity (reflected by 6 min walk distance), a surrogate for cardiopulmonary haemodynamics. Secondary end points included time to clinical worsening and change from baseline functional class.

Analysis of the primary end points (in 168 patients) showed a reduction in the mean pulmonary vascular resistance (35.2% of baseline value). The initial increase in exercise capacity also seen in the bosentan group was not statistically significant at 6 months. The overall number of adverse events was similar between groups, with syncope the most common serious adverse event in the bosentan group. The study was not sufficiently powered to perform any subgroup analysis. The EARLY study showed the potential benefit of bosentan in mildly symptomatic patients with pulmonary arterial hypertension, as reflected by improvement in haemodynamics and the prevention of clinical deterioration.


F Magdy

Correspondence to: Dr F Magdy, Junior Trainee in Cardiology, University Hospital of North Staffordshire, Stoke-on-Trent, UK; fmfouadissa@yahoo.co.uk